Clinical Trial Update: Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of single-agent sunitinib in chemo-refractory metastatic melanoma was terminated; the update notes the study status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: Krankenhaus Nordwest | Conditions: Chemo-refractory Melanoma | Phase 2 | Status: TERMINATED